Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

ABSTRACT:

Background

Breast cancer molecular prognostic tools that predict recurrence risk have mainly been established on endocrine-treated patients and thus are not optimal for the evaluation of benefit from endocrine therapy. The Stockholm tamoxifen (STO-3) trial which randomized postmenopausal node-negative patients to 2-year tamoxifen (followed by an optional randomization for an additional 3-year tamoxifen vs nil), versus no adjuvant treatment, provides a unique opportunity to evaluate long-term 20-year benefit of endocrine therapy within prognostic risk classes of the 70-gene prognosis signature that was developed on adjuvantly untreated patients.

Methods

We assessed by Kaplan-Meier analysis 20-year breast cancer-specific survival (BCSS) and 10-year distant metastasis-free surv

SUBMITTER: van 't Veer LJ 

PROVIDER: S-EPMC5668340 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature